Literature DB >> 12941902

Human T-cell leukemia virus type 1 envelope glycoprotein gp46 interacts with cell surface heparan sulfate proteoglycans.

Josefina D Piñon1, P J Klasse, Sushma R Jassal, Sandy Welson, Jonathan Weber, David W Brighty, Quentin J Sattentau.   

Abstract

The major receptors required for attachment and entry of the human T-cell leukemia virus type 1 (HTLV-1) remain to be identified. Here we demonstrate that a functional, soluble form of the HTLV-1 surface envelope glycoprotein, gp46, fused to an immunoglobulin Fc region (gp46-Fc) binds to heparan sulfate proteoglycans (HSPGs) on mammalian cells. Substantial binding of gp46-Fc to HeLa and Chinese hamster ovary (CHO) K1 cells that express HSPGs was detected, whereas binding to the sister CHO lines 2244, which expresses no HSPGs, and 2241, which expresses no glycosaminoglycans (GAGs), was much reduced. Enzymatic removal of HSPGs from HeLa and CHO K1 cells also reduced gp46-Fc binding. Dextran sulfate inhibited gp46-Fc binding to HSPG-expressing cells in a dose-dependent manner, whereas chondroitin sulfate was less effective. By contrast, dextran sulfate inhibited gp46-Fc binding to GAG-negative cells such as CHO 2244, CHO 2241, and Jurkat T cells weakly or not at all. Dextran sulfate inhibited HTLV-1 envelope glycoprotein (Env)-pseudotyped virus infection of permissive, HSPG-expressing target cells and blocked syncytium formation between HTLV-1 Env-expressing cells and HSPG-expressing permissive target cells. Finally, HSPG-expressing cells were more permissive for HTLV-1 Env-pseudotyped virus infection than HSPG-negative cells. Thus, similar to other pathogenic viruses, HTLV-1 may have evolved to use HSPGs as cellular attachment receptors to facilitate its propagation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12941902      PMCID: PMC224595          DOI: 10.1128/jvi.77.18.9922-9930.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  46 in total

Review 1.  Retrovirus receptors.

Authors:  Maja A Sommerfelt
Journal:  J Gen Virol       Date:  1999-12       Impact factor: 3.891

Review 2.  Functions of cell surface heparan sulfate proteoglycans.

Authors:  M Bernfield; M Götte; P W Park; O Reizes; M L Fitzgerald; J Lincecum; M Zako
Journal:  Annu Rev Biochem       Date:  1999       Impact factor: 23.643

3.  Soluble recombinant HTLV-1 surface glycoprotein competitively inhibits syncytia formation and viral infection of cells.

Authors:  S R Jassal; M D Lairmore; A J Leigh-Brown; D W Brighty
Journal:  Virus Res       Date:  2001-10-30       Impact factor: 3.303

4.  10E4 antigen of Scrapie lesions contains an unusual nonsulfated heparan motif.

Authors:  C Leteux; W Chai; K Nagai; C G Herbert; A M Lawson; T Feizi
Journal:  J Biol Chem       Date:  2001-01-16       Impact factor: 5.157

5.  Cell-surface proteoglycan expression by lymphocytes from peripheral blood and gingiva in health and periodontal disease.

Authors:  J F Manakil; P B Sugerman; H Li; G J Seymour; P M Bartold
Journal:  J Dent Res       Date:  2001-08       Impact factor: 6.116

6.  The HTLV receptor is a widely expressed protein.

Authors:  S R Trejo; L Ratner
Journal:  Virology       Date:  2000-03-01       Impact factor: 3.616

7.  Inducible expression of the cell surface heparan sulfate proteoglycan syndecan-2 (fibroglycan) on human activated macrophages can regulate fibroblast growth factor action.

Authors:  S Clasper; S Vekemans; M Fiore; M Plebanski; P Wordsworth; G David; D G Jackson
Journal:  J Biol Chem       Date:  1999-08-20       Impact factor: 5.157

8.  Human T-cell leukemia virus type 1 receptor expression among syncytium-resistant cell lines revealed by a novel surface glycoprotein-immunoadhesin.

Authors:  S R Jassal; R G Pöhler; D W Brighty
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

9.  'Chemical condoms' for the prevention of HIV infection: evaluation of novel agents against SHIV(89.6PD) in vitro and in vivo.

Authors:  J Weber; A Nunn; T O'Connor; D Jeffries; V Kitchen; S McCormack; J Stott; N Almond; A Stone; J Darbyshire
Journal:  AIDS       Date:  2001-08-17       Impact factor: 4.177

10.  A phase I study of a novel potential intravaginal microbicide, PRO 2000, in healthy sexually inactive women.

Authors:  L Van Damme; A Wright; K Depraetere; I Rosenstein; V Vandersmissen; L Poulter; M McKinlay; E Van Dyck; J Weber; A Profy; M Laga; V Kitchen
Journal:  Sex Transm Infect       Date:  2000-04       Impact factor: 3.519

View more
  45 in total

1.  A pH-sensitive heparin-binding sequence from Baculovirus gp64 protein is important for binding to mammalian cells but not to Sf9 insect cells.

Authors:  Chunxiao Wu; Shu Wang
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

2.  Distinct transformation tropism exhibited by human T lymphotropic virus type 1 (HTLV-1) and HTLV-2 is the result of postinfection T cell clonal expansion.

Authors:  Priya Kannian; Han Yin; Rami Doueiri; Michael D Lairmore; Soledad Fernandez; Patrick L Green
Journal:  J Virol       Date:  2012-01-25       Impact factor: 5.103

Review 3.  Tetraspanins in viral infections: a fundamental role in viral biology?

Authors:  F Martin; D M Roth; D A Jans; C W Pouton; L J Partridge; P N Monk; G W Moseley
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

4.  DC-SIGN facilitates fusion of dendritic cells with human T-cell leukemia virus type 1-infected cells.

Authors:  Pierre-Emmanuel Ceccaldi; Frédéric Delebecque; Marie-Christine Prevost; Arnaud Moris; Jean-Pierre Abastado; Antoine Gessain; Olivier Schwartz; Simona Ozden
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

5.  Neuropilin-1 is involved in human T-cell lymphotropic virus type 1 entry.

Authors:  David Ghez; Yves Lepelletier; Sophie Lambert; Jean-Marie Fourneau; Vincent Blot; Sébastien Janvier; Bertrand Arnulf; Peter M van Endert; Nikolaus Heveker; Claudine Pique; Olivier Hermine
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

6.  Human T-cell leukemia virus type 1 (HTLV-1) and HTLV-2 use different receptor complexes to enter T cells.

Authors:  Kathryn S Jones; Kazunori Fugo; Cari Petrow-Sadowski; Ying Huang; Daniel C Bertolette; Ivonne Lisinski; Samuel W Cushman; Steven Jacobson; Francis W Ruscetti
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

7.  The hypervariable region 1 of the E2 glycoprotein of hepatitis C virus binds to glycosaminoglycans, but this binding does not lead to infection in a pseudotype system.

Authors:  Arnab Basu; Aster Beyene; Keith Meyer; Ranjit Ray
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

8.  Candidate polyanionic microbicides inhibit human T-cell lymphotropic virus type 1 receptor interactions, cell-free infection, and cell-cell spread.

Authors:  Daniela Romer; David W Brighty; Cynthia L Robson; Quentin J Sattentau
Journal:  Antimicrob Agents Chemother       Date:  2008-12-01       Impact factor: 5.191

9.  HTLV-1 uses HSPG and neuropilin-1 for entry by molecular mimicry of VEGF165.

Authors:  Sophie Lambert; Manuella Bouttier; Roger Vassy; Michel Seigneuret; Cari Petrow-Sadowski; Sébastien Janvier; Nikolaus Heveker; Francis W Ruscetti; Gérard Perret; Kathryn S Jones; Claudine Pique
Journal:  Blood       Date:  2009-03-06       Impact factor: 22.113

10.  The receptor complex associated with human T-cell lymphotropic virus type 3 (HTLV-3) Env-mediated binding and entry is distinct from, but overlaps with, the receptor complexes of HTLV-1 and HTLV-2.

Authors:  Kathryn S Jones; Ying K Huang; Sébastien A Chevalier; Philippe V Afonso; Cari Petrow-Sadowski; Daniel C Bertolette; Antoine Gessain; Francis W Ruscetti; Renaud Mahieux
Journal:  J Virol       Date:  2009-03-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.